Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.

Mol Cancer Ther · 2023 · PMC10320479 · PMID 37186518

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

IHC examination of tumor-bearing lung tissues revealed a slight trend of decreased pERK in Compound A-treated animals ( Fig. 5D ; did not reach statistical significance), but no changes were detected in pAKT or pS6.

also in 1,229 other papers

an overall trendno p-value reported

IHC for pERK, pAKT, and pS6 showed significantly lower pAKT in the G12C KP animals but also modest decreases in pERK and pS6, suggesting an overall trend in reduced RAF–MEK–ERK and PI3K–AKT–mTOR signaling in the G12C-driven tumors compared to their G12D-driven counterparts (Supplementary Fig.

also in 1,675 other papers

did not reach statistical significanceno p-value reported

5D ; did not reach statistical significance), but no changes were detected in pAKT or pS6.

also in 34,328 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.